EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudie

Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial

Yu-Ming Ding, Qiu-Mei Zhang, Rui-Li Li, Zhong-Xue Han, Qing Zhao, Li-Dong Xu, Ke-Yu Wang, Xue-Ping Nan, Miao Duan, Shu-Yan Zeng, Qing-Zhou Kong, Hui Wang und 5 weitere

Helicobacter · 2024

DOI: 10.1111/hel.13121 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Helicobacter, 2024. Verfasst von Yu-Ming Ding und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Tetracycline, Bismuth, Anti-Bacterial Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current guidelines recommend bismuth‐containing quadruple therapy for patients newly diagnosed with Helicobacter pylori ( H. pylori ) infection. We aimed to compare the efficacy and safety of tetracycline administered three times daily versus four times daily in bismuth‐containing quadruple therapy for first‐line treatment of H. pylori infection.

Methods

This multicenter, noninferiority, randomized controlled study, conducted in China, recruited treatment‐naïve adults with H. pylori infection, randomized 1:1 into two treatment groups to receive either of the following bismuth‐containing quadruple therapies: esomeprazole 20 mg twice‐daily; bismuth 220 mg twice‐daily; amoxicillin 1000 mg twice‐daily; and tetracycline 500 mg three times daily (TET‐T) versus 500 mg four times daily (TET‐F). At least 6 weeks post‐treatment, a 13 C‐urea breath test was performed to evaluate H. pylori eradication.

Results

In total, 406 patients were randomly assigned to the two treatment groups. Intention‐to‐treat eradication rates were 91.63% (186/203; 95% confidence interval [CI] 87.82%–95.44%) versus 90.15% (183/203; 95% CI 86.05%–94.25%) ( p = 0.0005) and per‐protocol eradication rates were 95.34% (184/193; 95% CI 92.36%–98.31%) versus 95.72% (179/187; 95% CI 92.82%–98.62%) ( p = 0.0002) for the TET‐T and TET‐F group, respectively. TET‐T‐treated patients had a lower incidence of adverse effects than TET‐F‐treated patients (21.61% vs. 31.63%, p = 0.024), with no significant differences in compliance to treatment between the groups.

Conclusion

As a first‐line therapy for H. pylori infection, the eradication rate of the TET‐T therapy was noninferior to that of the TET‐F therapy while significantly reducing the incidence of adverse reactions. Trial Registration ClinicalTrials.gov identifier: NCT05431075

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsTetracyclineBismuthAnti-Bacterial AgentsDrug Therapy, CombinationHelicobacter pyloriHumansMaleMiddle AgedFemaleAdultTreatment OutcomeChinaAmoxicillinDrug Administration ScheduleEsomeprazoleAgedYoung AdultBreath TestsProton Pump Inhibitors

Stichwörter der Autor:innen

Helicobacter pyloriantibioticdosetetracycline

Substanzen

TetracyclineBismuthAnti-Bacterial AgentsAmoxicillinEsomeprazoleProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China.
  • Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong Province, China.
  • Shandong Provincial Clinical Research Center for Digestive Disease, Qilu Hospital of Shandong University, Jinan, Shandong Province, China.
  • Yuncheng Traditional Chinese Medicine Hospital, Heze, Shandong Province, China.
  • Taierzhuang District People's Hospital, Zaozhuang, Shandong Province, China.
  • Zibo Central Hospital, Zibo, Shandong Province, China.

ORCID-Profile: Xiu-Li Zuo, Yue-Yue Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Ding, Y. M., Zhang, Q. M., Li, R. L., Han, Z. X., Zhao, Q., Xu, L. D., Wang, K. Y., Nan, X. P., Duan, M., Zeng, S. Y., Kong, Q. Z., Wang, H., Wu, X. Q., Zhang, N., Li, Y. Q., Zuo, X. L., & Li, Y. Y. (2024). Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial. Helicobacter. https://doi.org/10.1111/hel.13121

Vancouver

Ding YM, Zhang QM, Li RL, Han ZX, Zhao Q, Xu LD, et al. Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial. Helicobacter. 2024. doi:10.1111/hel.13121

BibTeX
@article{Ding2024,
  author = {Ding, Yu-Ming and Zhang, Qiu-Mei and Li, Rui-Li and Han, Zhong-Xue and Zhao, Qing and Xu, Li-Dong and Wang, Ke-Yu and Nan, Xue-Ping and Duan, Miao and Zeng, Shu-Yan and Kong, Qing-Zhou and Wang, Hui and Wu, Xiao-Qi and Zhang, Ning and Li, Yan-Qing and Zuo, Xiu-Li and Li, Yue-Yue},
  title = {Tetracycline Three Times Daily Versus Four Times Daily in Bismuth‐Containing Quadruple Therapy as the First‐Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial},
  journal = {Helicobacter},
  year = {2024},
  doi = {10.1111/hel.13121}
}
Kostenlos starten →